Untitled

Abstract

Congenital hyperinsulinism is a condition, in which the beta cells of pancreas secrete an in appropriately excessive amount of insulin in relation to the existing blood glucose level. The treatment of diffuse form of HI is difficult and involves intensive medical therapy. Usually after a diagnosis of CHI is made, a trial of treatment with diazoxide is given for a short period [1]. However as most of the cases of severe CHIs are caused by genetic mutations of KATP channels, they are unresponsive to diazoxide [2]. A somatostatin analogue, octreotide has been successfully used for around 20yrs in cases of diazoxide-unresponsive CHI [3]. This requires 3-4 daily subcutaneous injections or the use of an insulin pump. Long acting somatostatin analogues, LAR octreotide and Lantreotide acetate have been recently used allowing once monthly injections instead of 84 S.C injections over 28 days [2]. We describe our experience with LAR octreoctide in a Kuwaiti child. Keywords: